Order byBest matchMost fresh

Sarepta, Elevidys

Digest more
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

Continue reading

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments
Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume
FDA allows Sarepta to resume some Elevidys shipments
The Food and Drug Administration has given Sarepta Therapeutics a green light to resume shipping its gene therapy Elevidys to some patients with Duchenne muscular dystrophy, a little over one week af...

Continue reading

Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys
Parents call on FDA for path forward after Duchenne's gene therapy pause | Morning in America
Sarepta's FDA woes raise questions for future of gene therapy treatments
While Sarepta’s challenges could push some away from investing in gene therapies, it could also lead to interest in different approaches.

Continue reading

FDA recommends lifting voluntary hold on Elevidys in ambulatory patients
STAT · 23h
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
Sarepta Soars After FDA Says Some Patients Can Get Elevidys
Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.
MIT Technology Review4d
The deadly saga of the controversial gene therapy Elevidys
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy
The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.
Roche Says CHMP Issued a Negative Opinion on the Conditional Marketing Authorisation for Elevidys
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Explore more
Feedback